To test the in vivo therapeutic potential of the single-AAV ABE system, we installed in mice mutations that are associated with decreased cardiovascular disease risk in humans55–57 by precisely knocking down Pcsk9 or Angptl3 protein levels. This evidence concerns the gene ANGPTL3 and cardiovascular disorder.